¼¼°èÀÇ ¸®¶ó±Û·çƼµå ¹× ¼¼¸¶±Û·çƼµå ½ÃÀå
Liraglutide and Semaglutide
»óǰÄÚµå : 1781393
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 451 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,180,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,541,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¸®¶ó±Û·çƼµå ¹× ¼¼¸¶±Û·çƼµå ¼¼°è ½ÃÀåÀº 2030³â±îÁö 298¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 171¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¸®¶ó±Û·çƼµå ¹× ¼¼¸¶±Û·çƼµå ¼¼°è ½ÃÀåÀº 2024-2030³â ºÐ¼® ±â°£ µ¿¾È CAGR 9.7%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 298¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Á¤Á¦´Â CAGR 8.0%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 174¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾×Á¦ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 12.5%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 46¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 13.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¸®¶ó±Û·çƼµå ¹× ¼¼¸¶±Û·çƼµå ½ÃÀåÀº 2024³â¿¡´Â 46¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 60¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 13.0%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 7.1%¿Í 8.4%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 7.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¸®¶ó±Û·çƼµå ¹× ¼¼¸¶±Û·çƼµå ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¸®¶ó±Û·çƼµå ¹× ¼¼¸¶±Û·çƼµå°¡ ´ç´¢º´ ¹× ºñ¸¸ Ä¡·á¿¡ º¯È­¸¦ °¡Á®¿Ã ¼ö ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

¸®¶ó±Û·çƼµå ¹× ¼¼¸¶±Û·çƼµå´Â ´ëÇ¥ÀûÀÎ ±Û·çÄ«°ï À¯»ç ÆéŸÀ̵å-1(GLP-1) ¼ö¿ëü ÀÛ¿ëÁ¦·Î¼­ Á¦2Çü ´ç´¢º´°ú ºñ¸¸ °ü¸®ÀÇ ÆÇµµ¸¦ ¹Ù²Û ¾à¹°·Î µîÀåÇß½À´Ï´Ù. ÀÌ ¾à¹°Àº Àν¶¸° ºÐºñ¸¦ ÃËÁøÇÏ°í ½Ä¿åÀ» ¾ïÁ¦Çϸç À§ ¹èÃâÀ» Áö¿¬½ÃÄÑ Ç÷´ç Á¶ÀýÀ» °³¼±Çϰí üÁßÀ» Å©°Ô °¨¼Ò½Ãŵ´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ´ç´¢º´°ú ºñ¸¸ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ±âÁ¸ Ç×´ç´¢º´Á¦ ´ëºñ ¿ì¼öÇÑ È¿°ú¸¦ ¹ßÈÖÇϱ⠶§¹®¿¡ À̵é Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. Àν¶¸° Ä¡·á¿Í ´Þ¸® ¸®¶ó±Û·çƼµå ¹× ¼¼¸¶±Û·çƼµå¿Í °°Àº GLP-1 ¼ö¿ëü ÀÛ¿ëÁ¦´Â ÀúÇ÷´ç À§ÇèÀ» ÁÙÀ̸鼭 üÁß Á¶ÀýÀ» ÃËÁøÇϱ⠶§¹®¿¡ ȯÀÚ¿Í ÀÇ·áÁø ¸ðµÎ¿¡°Ô ¸Å·ÂÀûÀÎ ¼±ÅÃÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ½ÉÇ÷°ü°è¿¡ ´ëÇÑ À¯¿ë¼ºÀ» µÞ¹ÞħÇÏ´Â ÀÓ»óÀû ±Ù°Å°¡ Áõ°¡ÇÔ¿¡ µû¶ó ±ÔÁ¦ ´ç±¹°ú ÀÇ·á ±â°üÀº Áö¼ÓÀûÀ¸·Î »ç¿ëÀ» ±ÇÀåÇϰí ÀÖÀ¸¸ç, äÅ÷üÀº ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¦¾à»çµéÀÌ ´õ ¸¹Àº ¿¬±¸¿Í Çõ½Å¿¡ ÅõÀÚÇϸ鼭 ´ë»ç¼º Áúȯ¿¡¼­ GLP-1 À¯»çüÀÇ ¿ªÇÒÀÌ È®´ëµÇ°í, ´ç´¢º´ ¹× üÁß Á¶Àý Ä¡·á¿¡¼­ ½ÃÀå¿¡¼­ÀÇ ÀÔÁö°¡ ´õ¿í °ø°íÇØÁú °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸±¶ó±Û·çƼµå¿Í ¼¼¸¶±Û·çƼµå Á¦Á¦ÀÇ ÃֽŠÇõ½ÅÀº ¹«¾ùÀΰ¡?

±â¼úÀÇ ¹ßÀü°ú ¿¬±¸ °³¹ß·Î ¸±¶ó±Û·çƼµå¿Í ¼¼¸¶±Û·çƼµåÀÇ Á¦ÇüÀÌ ´«¿¡ ¶ç°Ô °³¼±µÇ¾î È¿´É, ȯÀÚ ¼øÀÀµµ, Åõ¿© ÆíÀǼºÀÌ Çâ»óµÇ¾ú½À´Ï´Ù. °¡Àå Áß¿äÇÑ µ¹ÆÄ±¸ Áß Çϳª´Â °æ±¸¿ë ¼¼¸¶±Û·çƼµåÀÇ µµÀÔÀ¸·Î ÇÇÇÏ ÁÖ»çÀÇ Çʿ伺À» ¾ø¾Ö°í ȯÀÚ ¼øÀÀµµÀÇ Å« À庮À» ÇØ°áÇÑ °ÍÀÔ´Ï´Ù. ÀÌ Çõ½ÅÀº ƯÈ÷ ÁÖ»çÁ¦º¸´Ù °æ±¸¿ë ¾à¹°À» ¼±È£Çϴ ȯÀÚµé »çÀÌ¿¡¼­ Á¢±Ù¼ºÀ» È®´ëÇß½À´Ï´Ù. ¶ÇÇÑ, üÁß °¨·® È¿°ú¸¦ ÃÖÀûÈ­Çϰí Ç÷´ç Á¶ÀýÀ» °³¼±Çϱâ À§ÇØ ¼­¹æÇü Á¦Á¦ ¹× °í¿ë·® Á¦Á¦µµ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. GLP-1 ¼ö¿ëü ÀÛ¿ëÁ¦¿Í ³ªÆ®·ý Æ÷µµ´ç °ø¼ö¼Ûü-2(SGLT2) ¾ïÁ¦Á¦ µî ´Ù¸¥ ´ë»ç¼º ¾àÁ¦¿ÍÀÇ º´¿ë Åõ¿©µµ ´ç´¢º´ °ü¸®¿¡ ½Ã³ÊÁö È¿°ú¸¦ ³»±â À§ÇØ °ËÅäµÇ°í ÀÖ½À´Ï´Ù. Á¦¾à»çµéÀº ¶ÇÇÑ ºÒÆíÇÔÀ» ÃÖ¼ÒÈ­Çϸ鼭 Åõ¾àÀ» ¿ëÀÌÇÏ°Ô ÇÏ´Â ÇÁ¸®ÇÊµå Ææ°ú ÀÚµ¿ ÁÖ»ç±â¿¡µµ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ºñ¾ËÄڿüº Áö¹æ°£ Áúȯ(NAFLD) ¹× ½ÉÇ÷°üÁúȯ¿¡ Àû¿ëÇÏ´Â µî ÀÌµé ¾à¹°ÀÇ ±¤¹üÀ§ÇÑ Ä¡·á °¡´É¼ºÀ» Á¶»çÇÏ´Â ÀÓ»ó½ÃÇèÀÌ ÁøÇà ÁßÀ̸ç, ¸±¶ó±Û·çƼµå¿Í ¼¼¸¶±Û·çƼµåÀÇ Á¦Çü ¹ßÀüÀº ´ë»ç¼º Áúȯ Ä¡·áÀÇ ¹Ì·¡¸¦ °è¼Ó Çü¼ºÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼ö¿ä´Â GLP-1 Ä¡·áÁ¦ÀÇ ¼ºÀå¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÃÆ´Â°¡?

Á¦2Çü ´ç´¢º´°ú ºñ¸¸ÀÇ Áõ°¡·Î ÀÎÇØ ¸®¶ó±Û·çƼµå ¹× ¼¼¸¶±Û·çƼµå¿Í °°Àº GLP-1 ¼ö¿ëü ÀÛ¿ëÁ¦¿¡ ´ëÇÑ ¼¼°è ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ÀÇ·áÁøÀº ´ë»ç¼º Áúȯ¿¡ ´ëÇÑ È¿°úÀûÀ̰í Àå±âÀûÀÎ ÇØ°áÃ¥À» ¿ì¼±½ÃÇϰí ÀÖÀ¸¸ç, GLP-1 ¿ä¹ýÀº ³Î¸® ¹Þ¾Æµé¿©Áö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, üÁß °¨¼Ò¿Í ½ÉÇ÷°ü°è È¿°ú¸¦ ÃËÁøÇÏ´Â ºñÀν¶¸° ¿ä¹ý¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁø °Íµµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿ø°ÝÀÇ·á ¹× µðÁöÅÐ °Ç°­ Ç÷§ÆûÀÇ È®´ë·Î ¿Â¶óÀÎ Áø·á ¹× ÀüÀÚ Ã³¹æÀüÀÌ Ä¡·á ½ÃÀÛ°ú ¼øÀÀµµ¸¦ ÃËÁøÇÏ¿© ÀÌ·¯ÇÑ Ä¡·áÁ¦¿¡ ´ëÇÑ È¯ÀÚ Á¢±Ù¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °Ç°­¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ȯÀÚÀÇ ´ë»ç ÀÌ»ó¿¡ ´ëÇÑ Àû±ØÀûÀÎ °ü¸®µµ GLP-1 Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦¾à»çµéÀº ´ç´¢º´ ȯÀÚ»Ó¸¸ ¾Æ´Ï¶ó ºñ¸¸ °ü¸® ºÐ¾ß±îÁö Ÿ°ÙÀ¸·Î ¸¶ÄÉÆÃ È°µ¿À» È®´ëÇϰí ÀÖÀ¸¸ç, ÀÌ´Â Å« ¼ºÀå ±âȸ·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. º¸Çè »óȯ Á¤Ã¥ÀÌ ´õ À¯¸®ÇØÁö°í Á¦³×¸¯ ÀǾàǰÀÌ ½ÃÀå¿¡ ÁøÀÔÇÔ¿¡ µû¶ó ¸®¶ó±Û·çƼµå ¹× ¼¼¸¶±Û·çƼµå¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Çâ»óµÇ°í ´ë»ç ÀÌ»ó¿¡ ´ëÇÑ ±âº» Ä¡·áÁ¦·Î¼­ÀÇ ¿ªÇÒÀÌ °­È­µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸®¶ó±Û·çƼµå ¹× ¼¼¸¶±Û·çƼµå ½ÃÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¼ºÀå ¿äÀÎÀº ¹«¾ùÀΰ¡?

¸®¶ó±Û·çƼµå ¹× ¼¼¸¶±Û·çƼµå ½ÃÀåÀÇ ¼ºÀåÀº Àü ¼¼°è ºñ¸¸ ¹× ´ç´¢º´ À¯º´·ü Áõ°¡, Ä¡·á °¡À̵å¶óÀο¡¼­ GLP-1 ¼ö¿ëü ÀÛ¿ëÁ¦ÀÇ Ã¤Åà Áõ°¡, Áö¼ÓÀûÀÎ ÀǾàǰÀÇ ¹ßÀü µî ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á¿Í ȯÀÚ Áß½ÉÀÇ Ä¡·á°¡ °­Á¶µÇ¸é¼­ Ç÷´ç Á¶Àý°ú üÁß °ü¸®ÀÇ ÀÌÁ¡À» ¸ðµÎ Á¦°øÇÏ´Â Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, GLP-1 Ä¡·áÁ¦ÀÇ ½ÉÇ÷°ü°è¿¡ ´ëÇÑ ¿¬±¸ °á°ú°¡ È®´ëµÇ¸é¼­ GLP-1 Ä¡·áÁ¦´Â °íÀ§Ç豺 ´ç´¢º´ ȯÀڵ鿡°Ô ÇʼöÀûÀÎ Ä¡·áÁ¦·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °íÇ÷¾Ð, ÀÌ»óÁöÁúÇ÷Áõ µî ºñ¸¸ °ü·Ã ÇÕº´ÁõÀÌ ±ÞÁõÇÔ¿¡ µû¶ó ÀÇ·áÁøµéÀº GLP-1 ¼ö¿ëü ÀÛ¿ëÁ¦¸¦ ´Ù¾àÁ¦ º´¿ë¿ä¹ý¿¡ Æ÷ÇÔ½ÃŰ´Â µî Á¾ÇÕÀûÀÎ Ä¡·á Á¢±Ù¹ýÀ» äÅÃÇϰí ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ Áß¿äÇÑ ÃËÁø¿äÀÎÀº »õ·Î¿î GLP-1 ±â¹Ý Ä¡·áÁ¦ÀÇ °­·ÂÇÑ ÆÄÀÌÇÁ¶óÀÎÀ̸ç, Á¦¾à»çµéÀº È¿´ÉÀ» °³¼±ÇÏ°í ºÎÀÛ¿ëÀ» ÁÙÀ̸ç ȯÀÚÀÇ ¼øÀÀµµ¸¦ Çâ»ó½Ãų ¼ö ÀÖ´Â Â÷¼¼´ë Á¦Á¦ °³¹ß¿¡ Àû±ØÀûÀ¸·Î ³ª¼­°í ÀÖ½À´Ï´Ù. »ýȰ½À°ü °³¼±°ú ¿¹¹æÀû °Ç°­°ü¸®ÀÇ Ãß¼¼´Â ÀÌ·¯ÇÑ ¾à¹°ÀÇ Á¶±â äÅÃÀ» ´õ¿í ÃËÁøÇϰí Àå±âÀûÀÎ ´ë»ç¼º Áúȯ °ü¸®¿¡¼­ ÀÌ·¯ÇÑ ¾à¹°ÀÇ ¿ªÇÒÀ» È®°íÈ÷ Çϰí ÀÖ½À´Ï´Ù. ÀÎÁöµµ Çâ»ó, Á¢±Ù¼º °³¼±, Áö¼ÓÀûÀÎ ÀÇ·á ¹ßÀüÀ¸·Î ÀÎÇØ ½ÃÀå »óȲÀº Áö¼ÓÀûÀÎ ¼ºÀåÀ» ÀÌ·ç¸ç Àü ¼¼°è ´ç´¢º´ ¹× ºñ¸¸ Ä¡·áÀÇ ÆÇµµ¸¦ ¹Ù²Ü °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(Á¤Á¦, ¾×Á¦), Åõ¿© °æ·Î(ºñ°æ±¸ Åõ¿©, °æ±¸ Åõ¿©), À¯Åë ä³Î(º´¿ø ¾à±¹, ¼Ò¸Å ¾à±¹), ¿ëµµ(2Çü ´ç´¢º´, ºñ¸¸)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Liraglutide and Semaglutide Market to Reach US$29.8 Billion by 2030

The global market for Liraglutide and Semaglutide estimated at US$17.1 Billion in the year 2024, is expected to reach US$29.8 Billion by 2030, growing at a CAGR of 9.7% over the analysis period 2024-2030. Pills, one of the segments analyzed in the report, is expected to record a 8.0% CAGR and reach US$17.4 Billion by the end of the analysis period. Growth in the Liquid segment is estimated at 12.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.6 Billion While China is Forecast to Grow at 13.0% CAGR

The Liraglutide and Semaglutide market in the U.S. is estimated at US$4.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.0 Billion by the year 2030 trailing a CAGR of 13.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.1% and 8.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.6% CAGR.

Global Liraglutide and Semaglutide Market - Key Trends & Drivers Summarized

Why Are Liraglutide and Semaglutide Transforming Diabetes and Obesity Treatment?

Liraglutide and semaglutide, two prominent glucagon-like peptide-1 (GLP-1) receptor agonists, have emerged as game-changers in the management of type 2 diabetes and obesity. These medications work by enhancing insulin secretion, suppressing appetite, and slowing gastric emptying, leading to improved blood sugar control and significant weight loss. The increasing prevalence of diabetes and obesity worldwide has driven a surge in demand for these therapeutics, as they offer superior efficacy compared to traditional antidiabetic medications. Unlike insulin therapy, GLP-1 receptor agonists like liraglutide and semaglutide provide a lower risk of hypoglycemia while promoting weight management, making them an attractive choice for patients and healthcare providers alike. With growing clinical evidence supporting their cardiovascular benefits, regulatory agencies and medical organizations continue to endorse their use, further boosting adoption rates. As pharmaceutical companies invest in further research and innovation, the role of these GLP-1 analogs in metabolic disorders is expected to expand, solidifying their market position in diabetes and weight management therapies.

What Are the Latest Innovations in Liraglutide and Semaglutide Formulations?

Technological advancements and research developments have led to notable improvements in the formulations of liraglutide and semaglutide, enhancing their effectiveness, patient compliance, and administration convenience. One of the most significant breakthroughs is the introduction of oral semaglutide, which eliminates the need for subcutaneous injections, addressing a major barrier to patient adherence. This innovation has expanded accessibility, particularly among individuals who prefer oral medications over injectables. Additionally, sustained-release formulations and higher-dose versions have been developed to optimize weight loss outcomes and improve glycemic control. The combination of GLP-1 receptor agonists with other metabolic drugs, such as sodium-glucose co-transporter-2 (SGLT2) inhibitors, is also being explored to create synergistic effects in diabetes management. Pharmaceutical companies are also investing in pre-filled pens and auto-injectors that enhance ease of administration while minimizing discomfort. With ongoing clinical trials investigating the broader therapeutic potential of these drugs, including applications in non-alcoholic fatty liver disease (NAFLD) and cardiovascular health, the formulation advancements in liraglutide and semaglutide continue to shape the future of metabolic disease treatment.

How Is Market Demand Influencing the Growth of GLP-1 Therapies?

The global demand for GLP-1 receptor agonists such as liraglutide and semaglutide has surged due to the rising burden of type 2 diabetes and obesity, both of which have reached epidemic proportions. With healthcare providers prioritizing effective and long-term solutions for metabolic diseases, GLP-1 therapies have gained widespread acceptance. The growing preference for non-insulin therapies that promote weight loss and cardiovascular benefits has further contributed to their market expansion. Additionally, the expansion of telehealth and digital health platforms has improved patient access to these medications, as online consultations and e-prescriptions facilitate treatment initiation and adherence. The rising health awareness and proactive management of metabolic disorders among patients have also driven the demand for GLP-1 therapies, as individuals seek treatments that align with holistic wellness goals. Furthermore, pharmaceutical companies are expanding their marketing efforts, targeting not only diabetes patients but also the obesity management sector, which represents a significant growth opportunity. As reimbursement policies become more favorable and generic alternatives enter the market, accessibility to liraglutide and semaglutide is expected to increase, reinforcing their role as cornerstone treatments for metabolic disorders.

What Are the Primary Growth Drivers Fueling the Liraglutide and Semaglutide Market?

The growth in the liraglutide and semaglutide market is driven by several key factors, including the rising global prevalence of obesity and diabetes, increased adoption of GLP-1 receptor agonists in treatment guidelines, and continuous pharmaceutical advancements. The increasing emphasis on personalized medicine and patient-centered care has bolstered demand for therapies that offer both glycemic control and weight management benefits. Additionally, expanding research into the cardiovascular benefits of GLP-1 therapies has further positioned these medications as essential treatments for high-risk diabetic patients. The surge in obesity-related comorbidities, such as hypertension and dyslipidemia, has also prompted healthcare providers to adopt a holistic treatment approach, integrating GLP-1 receptor agonists into multimodal therapy plans. Another crucial growth driver is the strong pipeline of novel GLP-1-based treatments, with pharmaceutical companies actively developing next-generation formulations that improve efficacy, reduce side effects, and enhance patient adherence. The growing trend of lifestyle modifications and preventive healthcare initiatives has further encouraged early adoption of these medications, solidifying their role in long-term metabolic disease management. With increasing awareness, improved accessibility, and continuous medical advancements, the liraglutide and semaglutide market is set to witness sustained growth, transforming the landscape of diabetes and obesity treatment worldwide.

SCOPE OF STUDY:

The report analyzes the Liraglutide and Semaglutide market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Pills, Liquid); Administration Route (Parenteral Administration, Oral Administration); Distribution Channel (Hospital Pharmacies, Retail Pharmacies); Application (Type 2 Diabetes Mellitus, Obesity)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â